



## 20th Anniversary of Pharmaceuticals—Met Receptor

Guest Editors:

**Prof. Dr. Tiziana Crepaldi**

Department of Oncology,  
Candiolo Cancer Institute,  
University of Turin, FPO-IRCCS,  
Candiolo, Italy

**Dr. Simona Gallo**

Department of Oncology,  
Candiolo Cancer Institute,  
University of Turin, FPO-IRCCS  
Strada Provinciale 142, 10060  
Candiolo, Italy

Deadline for manuscript  
submissions:

**25 September 2024**

### Message from the Guest Editors

Dear Colleagues,

Novel MET-targeted therapies have emerged as promising approaches in cancer treatment. One such approach involves the development of highly selective small-molecule inhibitors that specifically target the MET kinase domain, blocking its activity and downstream signaling pathways. Another innovative strategy utilizes engineered MET-targeted antibodies or bispecific antibodies that simultaneously target MET and another cancer-associated protein, enhancing the efficacy of MET inhibition and potentially overcoming resistance mechanisms. These novel therapies hold great potential for personalized cancer treatment and are being actively investigated in preclinical and clinical settings. This Special Issue invites submissions covering various aspects of recent research related to the newly discovered physiological and pathological functions and regulatory mechanisms of the MET proto-oncogene, as indicated previously.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)